Skip to main content
. Author manuscript; available in PMC: 2020 Sep 30.
Published in final edited form as: Surg Oncol. 2018 May 11;27(3):433–440. doi: 10.1016/j.suronc.2018.05.017

Table 4.

Effects of postoperative radiotherapy on survival based on sarcoma dominance patterns for stage I-III disease (n = 772).

Characteristic Progression-free survival
 Cause-specific survival
HR (95%CI) P-value HR (95%CI) P-value
Homologous/dominance (−)
 Radiotherapy (−) 1 1
 Radiotherapy (+) 0.90 (0.60–1.36) 0.62 1.02 (0.63–1.68) 0.92
Heterologous/dominance (−)
 Radiotherapy (−) 1 1
 Radiotherapy (+) 0.74 (0.44–1.24) 0.25 (0.29–1.26) 0.17
Homologous/dominance (+)
 Radiotherapy (−) 1 1
 Radiotherapy (+) 0.49 (0.26–0.92) 0.026 0.37 (0.16–0.86) 0.021
Heterologous/dominance (+)
 Radiotherapy (−) 1 1
 Radiotherapy (+) 0.36 (0.18–0.70) 0.003 0.35 (0.16–0.77) 0.009

Cox proportional hazard regression test for P-values (adjusted for age, stage, and chemotherapy use). Significant P-values are emboldened. Abbreviations: HR, hazard ratio; and CI, confidence interval.